2025 | 2024 | 2023 | 2022 | 2021

2025

Zhao Y, Gulati R, Yang Z, Newcomb L, Zheng Y, Zhu K, Liu M, Heijnsdijk EAM, Haffner MC, Cooperberg M, Eggener SE, De Marzo AM, Kibel AS, Rizopoulos D, Hall IJ, Etzioni R. Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabeling. J Natl Cancer Inst. 2025 Apr 1;117(4):685-691.

Raychaudhuri R, DeJong M, Rettig M, Yu EY, Gulati R, Schweizer MT, Nelson PS, Pritchard CC, Montgomery B, Cheng HH. Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD Trial. Eur Urol. 2025 Mar;87(3):375-376.

Goddard KAB, Feuer EJ, Mandelblatt JS, Meza R, Holford TR, Jeon J, Lansdorp-Vogelaar I, Gulati R, Stout NK, Howlader N, Knudsen AB, Miller D, Caswell-Jin JL, Schechter CB, Etzioni R, Trentham-Dietz A, Kurian AW, Plevritis SK, Hampton JM, Stein S, Sun LP, Umar A, Castle PE. Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020. JAMA Oncol. 2025 Feb 1;11(2):162-167.

2024

Owens L, Brahme O, Gulati R, Etzioni R. Trends in age and prostate-specific antigen at prostate cancer diagnosis between 2010 and 2019. JNCI Cancer Spectr. 2024 Nov 1;8(6):pkae106.

Gulati R, Jiao B, Al-Faouri R, Sharma V, Kaul S, Fleishman A, Wymer K, Boorjian SA, Olumi AF, Etzioni R, Gershman B. Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis. Ann Intern Med. 2024 Jul;177(7):871-881.

Wright JL, Schenk JM, Gulati R, Beatty SJ, VanDoren M, Lin DW, Porter MP, Morrissey C, Dash A, Gore JL, Etzioni R, Plymate SR, Neuhouser ML. The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance. Cancer. 2024 Jun 15;130(12):2108-2119.

Lange JM, Gogebakan KC, Gulati R, Etzioni R. Projecting the Impact of Multi-Cancer Early Detection on Late-Stage Incidence Using Multi-State Disease Modeling. Cancer Epidemiol Biomarkers Prev. 2024 Jun 3;33(6):830-837.

Ajkunic A, Sayar E, Roudier MP, Patel RA, Coleman IM, De Sarkar N, Hanratty B, Adil M, Zhao J, Zaidi S, True LD, Sperger JM, Cheng HH, Yu EY, Montgomery RB, Hawley JE, Ha G, Persse T, Galipeau P, Lee JK, Harmon SA, Corey E, Lang JM, Sawyers CL, Morrissey C, Schweizer MT, Gulati R, Nelson PS, Haffner MC. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates. NPJ Precis Oncol. 2024 May 17;8(1):104.

Lee KM, Nelson TJ, Bryant A, Teerlink CC, Gulati R, Pagadala MS, Tcheandjieu C, Pridgen KM, DuVall SL, Yamoah K, Vassy JL, Seibert TM, Hauger RL, Rose BS, Lynch JA. Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry. J Natl Cancer Inst. 2024 May 8;116(5):753-757.

Webb AB, Berg CD, Castle PE, Crosby D, Etzioni R, Kessler LG, Menon U, Parmar M, Steele RJC, Sasieni PD. Considerations for using potential surrogate endpoints in cancer screening trials. Lancet Oncol. 2024 May;25(5):e183-e192.

Raychaudhuri R, Mo G, Tuchayi AM, Graham L, Gulati R, Pritchard CC, Haffner MC, Yezefski T, Hawley JE, Cheng HH, Yu EY, Grivas P, Montgomery RB, Nelson PS, Chen DL, Hope T, Iravani A, Schweizer MT. Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort Study. JCO Precis Oncol. 2024 Apr;8:e2300634.

Feng X, Zahed H, Onwuka J, Callister MEJ, Johansson M, Etzioni R, Robbins HA. Cancer stage compared with mortality as end points in randomized clinical trials of cancer screening: a systematic review and meta-analysis. JAMA. 2024 Apr 7:e245814.

Lange JM, Gogebakan KC, Gulati R, Etzioni R. Projecting the impact of multi- cancer early detection on late-stage incidence using multi-state disease modeling. Cancer Epidemiol Biomarkers Prev. 2024 Mar 20.

Schoen MW, Montgomery RB, Owens L, Khan S, Sanfilippo KM, Etzioni RB. Survival in patients with de novo metastatic prostate cancer. JAMA Netw Open. 2024 Mar 4;7(3):e241970.

Hammarlund N, Holt SK, Basu A, Etzioni R, Morehead D, Lee JR, Wolff EM, Gore JL, Nyame YA. Isolating the drivers of racial inequities in prostate cancer treatment. Cancer Epidemiol Biomarkers Prev. 2024 Mar 1;33(3):435-441.

Baker SG, Etzioni R. Prediagnostic evaluation of multicancer detection tests: design and analysis considerations. J Natl Cancer Inst. 2024 Feb 28:djae050.

Wright JL, Schenk JM, Gulati R, Beatty SJ, VanDoren M, Lin DW, Porter MP, Morrissey C, Dash A, Gore JL, Etzioni R, Plymate SR, Neuhouser ML. The Prostate Cancer Active Lifestyle Study (PALS): a randomized controlled trial of diet and exercise in overweight and obese men on active surveillance. Cancer. 2024 Feb 14.

Etzioni R, Gulati R, Patriotis C, Rutter C, Zheng Y, Srivastava S, Feng Z. Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologies. J Natl Cancer Inst. 2024 Feb 8;116(2):189-193.

Wolf AMD, Oeffinger KC, Shih TY, Walter LC, Church TR, Fontham ETH, Elkin EB, Etzioni RD, Guerra CE, Perkins RB, Kondo KK, Kratzer TB, Manassaram-Baptiste D, Dahut WL, Smith RA. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2024 Jan-Feb;74(1):50-81.

Caruana M, Gulati R, Etzioni R, Barratt A, Armstrong BK, Chiam K, Nair- Shalliker V, Luo Q, Bang A, Grogan P, Smith DP, O'Connell DL, Canfell K. Benefits and harms of prostate specific antigen testing according to Australian guidelines. Int J Cancer. 2024 Feb 15;154(4):648-658.

Lee KM, Nelson T, Bryant A, Teerlink C, Gulati R, Pagadala M, Tcheandjieu C, Pridgen KM, DuVall SL, Yamoah K, Vassy JL, Seibert TM, Hauger R, Rose BS, Lynch JA. Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry. J Natl Cancer Inst. 2024 Jan 11:djae002.

Kensler KH, Johnson R, Morley F, Albrair M, Dickerman BA, Gulati R, Holt SK, Iyer HS, Kibel AS, Lee JR, Preston MA, Vassy JL, Wolff EM, Nyame YA, Etzioni R, Rebbeck TR. Prostate cancer screening in African American men: a review of the evidence. J Natl Cancer Inst. 2024 Jan 10;116(1):34-52.

Patel RA, Sayar E, Coleman I, Roudier MP, Hanratty B, Low JY, Jaiswal N, Ajkunic A, Dumpit R, Ercan C, Salama N, O'Brien VP, Isaacs WB, Epstein JI, De Marzo AM, Trock BJ, Luo J, Brennen WN, Tretiakova M, Vakar-Lopez F, True LD, Goodrich DW, Corey E, Morrissey C, Nelson PS, Hurley PJ, Gulati R, Haffner MC. Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer. J Pathol. 2024 Jan;262(1):105-120.

2023

Gard CC, Lange J, Miglioretti DL, O'Meara ES, Lee CI, Etzioni R. Risk of cancer versus risk of cancer diagnosis? accounting for diagnostic bias in predictions of breast cancer risk by race and ethnicity. J Med Screen. 2023 Dec;30(4):209-216.

Post C, Braun TP, Etzioni R, Nabavizadeh N. Multicancer early detection tests: an overview of early results from prospective clinical studies and opportunities for oncologists. JCO Oncol Pract. 2023 Dec;19(12):1111-1115.

Park J, Lim F, Prest M, Ferris JS, Aziz Z, Agyekum A, Wagner S, Gulati R, Hur C. Quantifying the potential benefits of early detection for pancreatic cancer through a counterfactual simulation modeling analysis. Sci Rep. 2023 Nov 16;13(1):20028.

Gulati R, Nyame YA, Lange JM, Shoag JE, Tsodikov A, Etzioni R. Racial disparities in prostate cancer mortality: a model-based decomposition of contributing factors. J Natl Cancer Inst Monogr. 2023 Nov 8;2023(62):212-218.

Weiss NS, Etzioni R. Screening for cancer precursor lesions: assessing the impact on cancer incidence in randomized trials. Epidemiology. 2023 Nov 1;34(6):906-908.

Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine SW, Han M, Kim SK, Kirkby E, Konety BR, Miner M, Moses K, Nissenberg MG, Pinto PA, Salami SS, Souter L, Thompson IM, Lin DW. Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening. J Urol. 2023 Jul;210(1):46-53.

Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine SW, Han M, Kim SK, Kirkby E, Konety BR, Miner M, Moses K, Nissenberg MG, Pinto PA, Salami SS, Souter L, Thompson IM, Lin DW. Early detection of prostate cancer: AUA/SUO guideline part II: considerations for a prostate biopsy. J Urol. 2023 Jul;210(1):54-63.

Lange J, Zhao Y, Gogebakan KC, Olivas-Martinez A, Ryser MD, Gard CC, Etzioni R. Test sensitivity in a prospective cancer screening program: a critique of a common proxy measure. Stat Methods Med Res. 2023 Jun;32(6):1053-1063.

Owens L, Gogebakan KC, Menon U, Gulati R, Weiss NS, Etzioni R. Short-term Endpoints for Cancer Screening Trials: Does Tumor Subtype Matter? Cancer Epidemiol Biomarkers Prev. 2023 Jun 1;32(6):741-743.

Bhatia V, Kamat NV, Pariva TE, Wu LT, Tsao A, Sasaki K, Sun H, Javier G, Nutt S, Coleman I, Hitchcock L, Zhang A, Rudoy D, Gulati R, Patel RA, Roudier MP, True LD, Srivastava S, Morrissey CM, Haffner MC, Nelson PS, Priceman SJ, Ishihara J, Lee JK. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat Commun. 2023 Apr 11;14(1):2041.

Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall'Era M, Davis JW, Drake BF, Epstein JI, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, Kauffman E, Kaye D, Kibel AS, LaGrange CA, Maroni P, Ponsky L, Reys B, Salami SS, Sanchez A, Seibert TM, Shaneyfelt TM, Smaldone MC, Sonn G, Tyson MD, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi RA, Freedman- Cass DA. NCCN guidelines® insights: prostate cancer early detection, version 1.2023. J Natl Compr Canc Netw. 2023 Mar;21(3):236-246.

Etzioni R, Castle PE. Shopping for new cancer screening tests. J Clin Oncol. 2023 May 10;41(14):2471-2473.

Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P, Low JY, Hanratty B, Ang LS, Bhatia V, Adil M, Bakbak H, Quigley DA, Schweizer MT, Hawley JE, Kollath L, True LD, Feng FY, Bander NH, Corey E, Lee JK, Morrissey C, Gulati R, Nelson PS, Haffner MC. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight. 2023 Apr 10;8(7):e162907.

Nyame YA, Holt SK, Etzioni RD, Gore JL. Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer. Cancer. 2023 Feb 13.

Pinsky P, Lange J, Etzioni R. Estimating stage-specific sensitivity for cancer screening tests. J Med Screen. 2023 Feb 3:9691413231154801.

Schweizer MT, True L, Gulati R, Zhao Y, Ellis W, Schade G, Montgomery B, Goyal S, Nega K, Hakansson AK, Liu Y, Davicioni E, Pienta K, Nelson PS, Lin D, Wright J. Reply by authors. J Urol. 2023 Feb;209(2):362-363.

Schweizer MT, True L, Gulati R, Zhao Y, Ellis W, Schade G, Montgomery B, Goyal S, Nega K, Hakansson AK, Liu Y, Davicioni E, Pienta K, Nelson PS, Lin D, Wright J. Pathological effects of apalutamide in lower-risk prostate cancer: results from a phase II clinical trial. J Urol. 2023 Feb;209(2):354-363.

Devasia TP, Mariotto AB, Nyame YA, Etzioni R. Estimating the number of men living with metastatic prostate cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2023 Jan 30:EPI-22-1038.

Gogebakan KC, Lange J, Slatore CG, Etzioni R. Modeling the impact of novel systemic treatments on lung cancer screening benefits. Cancer. 2023 Jan 15;129(2):226-234.

Cheng HH, Sokolova AO, Gulati R, Bowen D, Knerr SA, Klemfuss N, Grivas P, Hsieh A, Lee JK, Schweizer MT, Yezefski T, Zhou A, Yu EY, Nelson PS, Montgomery B. Internet-based germline genetic testing for men with metastatic prostate cancer. JCO Precis Oncol. 2023 Jan;7:e2200104.

2022

Ghali F, Zhao Y, Patel D, Jewell T, Yu EY, Grivas P, Montgomery RB, Gore JL, Etzioni RB, Wright JL. Surrogate endpoints as predictors of overall survival in metastatic urothelial cancer: a trial-level analysis. Eur Urol Open Sci. 2022 Dec 15;47:58-64.

Schweizer MT, Gulati R, Yezefski T, Cheng HH, Mostaghel E, Haffner MC, Patel RA, De Sarkar N, Ha G, Dumpit R, Woo B, Lin A, Panlasigui P, McDonald N, Lai M, Nega K, Hammond J, Grivas P, Hsieh A, Montgomery B, Nelson PS, Yu EY. Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022 Dec 23.

Gulati R. Reducing prostate cancer overdiagnosis. N Engl J Med. 2022 Dec 8;387(23):2187-2188.

Bakbak H, Sayar E, Kaur HB, Salles DC, Patel RA, Hicks J, Lotan TL, De Marzo AM, Gulati R, Epstein JI, Haffner MC. Clonal relationships of adjacent Gleason pattern 3 and Gleason pattern 5 lesions in Gleason scores 3+5=8 and 5+3=8. Hum Pathol. 2022 Dec;130:18-24.

Keeney E, Sanghera S, Martin RM, Gulati R, Wiklund F, Walsh EI, Donovan JL, Hamdy F, Neal DE, Lane JA, Turner EL, Thom H, Clements MS. Cost-effectiveness analysis of prostate cancer screening in the UK: a decision model analysis based on the CAP trial. Pharmacoeconomics. 2022 Dec;40(12):1207-1220.

Gulati R, Nyame YA. Editorial comment. J Urol. 2022 Nov;208(5):1027.

Ryser MD, Etzioni RB. Estimation of breast cancer overdiagnosis in a US breast screening cohort. Ann Intern Med. 2022 Oct;175(10):W116-W117.

Nyame YA, Cooperberg MR, Cumberbatch MG, Eggener SE, Etzioni R, Gomez SL, Haiman C, Huang F, Lee CT, Litwin MS, Lyratzopoulos G, Mohler JL, Murphy AB, Pettaway C, Powell IJ, Sasieni P, Schaeffer EM, Shariat SF, Gore JL. Deconstructing, addressing, and eliminating racial and ethnic inequities in prostate cancer care. Eur Urol. 2022 Oct;82(4):341-351.

Patel NA, Sedrakyan A, Bianco F, Etzioni R, Gorin MA, Hsu WC, Mao J, Nguyen PL, Schaeffer E, Shoag J, Vickers A, Hu JC. Corrigendum to definitive and sustained increase in prostate cancer metastases in the United States. Urol Oncol. 2022 Jul;40(7):354.

Owens L, Gulati R, Etzioni R. Stage shift as an endpoint in cancer screening trials: implications for evaluating multicancer early detection tests. Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1298-1304.

Basourakos SP, Gulati R, Vince RA Jr, Spratt DE, Lewicki PJ, Hill A, Nyame YA, Cullen J, Markt SC, Barbieri CE, Hu JC, Trapl E, Shoag JE. Harm-to-benefit of three decades of prostate cancer screening in Black men. NEJM Evid. 2022 Jun;1(6).

Psutka SP, Gulati R, Jewett MAS, Fadaak K, Finelli A, Legere L, Morgan TM, Pierorazio PM, Allaf ME, Herrin J, Lohse CM, Houston Thompson R, Boorjian SA, Atwell TD, Schmit GD, Costello BA, Shah ND, Leibovich BC. A clinical decision aid to support personalized treatment selection for patients with clinical T1 renal masses: results from a multi-institutional competing-risks analysis. Eur Urol. 2022 Jun;81(6):576-585.

Heijnsdijk EAM, Gulati R, Lange JM, Tsodikov A, Roberts R, Etzioni R. Evaluation of prostate cancer screening strategies in a low-resource, high-risk population in the Bahamas. JAMA Health Forum. 2022 May 20;3(5):e221116.

Etzioni R, Lange J. Cancer modeling as learning experience. Cancer Epidemiol Biomarkers Prev. 2022 Apr 1;31(4):702-703.

Ryser MD, Lange J, Inoue LYT, O'Meara ES, Gard C, Miglioretti DL, Bulliard JL, Brouwer AF, Hwang ES, Etzioni RB. Estimation of breast cancer overdiagnosis in a US breast screening cohort. Ann Intern Med. 2022 Apr;175(4):471-478.

Beatty JD, Sun Q, Markowitz D, Chubak J, Huang B, Etzioni R. Identifying breast cancer recurrence histories via patient-reported outcomes. J Cancer Surviv. 2022 Apr;16(2):388-396.

Etzioni R, Gulati R, Weiss NS. Multicancer early detection: learning from the past to meet the future. J Natl Cancer Inst. 2022 Mar 8;114(3):349-352.

Maxwell KN, Cheng HH, Powers J, Gulati R, Ledet EM, Morrison C, Le A, Hausler R, Stopfer J, Hyman S, Kohlmann W, Naumer A, Vagher J, Greenberg SE, Naylor L, Laurino M, Konnick EQ, Shirts BH, AlDubayan SH, Van Allen EM, Nguyen B, Vijai J, Abida W, Carlo MI, Dubard-Gault M, Lee DJ, Maese LD, Mandelker D, Montgomery B, Morris MJ, Nicolosi P, Nussbaum RL, Schwartz LE, Stadler Z, Garber JE, Offit K, Schiffman JD, Nelson PS, Sartor O, Walsh MF, Pritchard CC. Inherited TP53 variants and risk of prostate cancer. Eur Urol. 2022 Mar;81(3):243-250.

Jiao B, Gulati R, Katki HA, Castle PE, Etzioni R. A quantitative framework to study potential benefits and harms of multi-cancer early detection testing. Cancer Epidemiol Biomarkers Prev. 2022 Jan;31(1):38-44.

2021

Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, Paller CJ, Sartor O, Castro E, Antonarakis ES, Cheng HH. Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. Prostate. 2021 Dec;81(16):1382-1389.

Lange J, Remmers S, Gulati R, Bill-Axelson A, Johansson JE, Kwiatkowski M, Auvinen A, Hugosson J, Hu JC, Roobol MJ, Carlsson SV, Etzioni R. Impact of cancer screening on metastasis: a prostate cancer case study. J Med Screen. 2021 Dec;28(4):480-487.

Etzioni R, Haffner MC, Gulati R. Divining harm-benefit tradeoffs of magnetic resonance imaging-targeted biopsy. Eur Urol. 2021 Nov;80(5):573-574.

Hendrix N, Gulati R, Jiao B, Kader AK, Ryan ST, Etzioni R. Clarifying the trade-offs of risk-stratified screening for prostate cancer: a cost- effectiveness study. Am J Epidemiol. 2021 Oct 1;190(10):2064-2074.

Nyame YA, Gulati R, Heijnsdijk EAM, Tsodikov A, Mariotto AB, Gore JL, Etzioni R. The impact of intensifying prostate cancer screening in Black men: a model-based analysis. J Natl Cancer Inst. 2021 Oct 1;113(10):1336-1342.

Gogebakan KC, Mukherjee K, Berry EG, Sonmez K, Leachman SA, Etzioni R. Impact of novel systemic therapies on the first-year costs of care for melanoma among Medicare beneficiaries. Cancer. 2021 Aug 15;127(16):2926-2933.

Zelner J, Riou J, Etzioni R, Gelman A. Accounting for uncertainty during a pandemic. Patterns (N Y). 2021 Aug 13;2(8):100310.

Jiao B, Gulati R, Hendrix N, Gore JL, Rais-Bahrami S, Morgan TM, Etzioni R. Economic evaluation of urine-based or magnetic resonance imaging reflex tests in men with intermediate prostate-specific antigen levels in the United States. Value Health. 2021 Aug;24(8):1111-1117.

Gulati R, Carlsson SV, Etzioni R. When to discuss prostate cancer screening with average-risk men. Am J Prev Med. 2021 Aug;61(2):294-298.

Etzioni R, Shen Y, Shih YT. Identifying preferred breast cancer risk predictors: a holistic perspective. J Natl Cancer Inst. 2021 Jun 1;113(6):660-661.

Etzioni R, Nyame YA. Prostate cancer screening guidelines for Black men: spotlight on an empty stage. J Natl Cancer Inst. 2021 Jun 1;113(6):650-651.

Graham LS, True LD, Gulati R, Schade GR, Wright J, Grivas P, Yezefski T, Nega K, Alexander K, Hou WM, Yu EY, Montgomery B, Mostaghel EA, Matsumoto AA, Marck B, Sharifi N, Ellis WJ, Reder NP, Lin DW, Nelson PS, Schweizer MT. Targeting backdoor androgen synthesis through AKR1C3 inhibition: a presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. Prostate. 2021 May;81(7):418-426.

Shih YT, Dong W, Xu Y, Etzioni R, Shen Y. Incorporating baseline breast density when screening women at average risk for breast cancer : a cost- effectiveness analysis. Ann Intern Med. 2021 May;174(5):602-612.

Brady L, Kriner M, Coleman I, Morrissey C, Roudier M, True LD, Gulati R, Plymate SR, Zhou Z, Birditt B, Meredith R, Geiss G, Hoang M, Beechem J, Nelson PS. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat Commun. 2021 Mar 3;12(1):1426.

Aleshin-Guendel S, Lange J, Goodman P, Weiss NS, Etzioni R. A latent disease model to reduce detection bias in cancer risk prediction studies. Eval Health Prof. 2021 Mar;44(1):42-49.

Nyame YA, Gulati R, Tsodikov A, Gore JL, Etzioni R. Prostate-specific antigen screening and recent increases in advanced prostate cancer. JNCI Cancer Spectr. 2020 Oct 26;5(1):pkaa098.